Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus-Induced liver disease

Liver Transplantation

Volumn 17, Issue 3, 2011, Pages 279-288

  Eurich, Dennis ^a   Bahra, Marcus ^a   Boas Knoop, Sabine ^a   Lock, Johan F ^a   Golembus, Jennifer ^a   Neuhaus, Ruth ^a   Neuhaus, Peter ^a   Neumann, Ulf P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RIBAVIRIN; SILIBININ; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ALLELE; ANTIVIRAL THERAPY; ARTICLE; CODON; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DONOR; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT; LIVER GRAFT FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REINFECTION; SEX DIFFERENCE; VIRUS GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOPSY; CHI-SQUARE DISTRIBUTION; CHILD; CODON; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GERMANY; GRAFT REJECTION; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952392506     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22190     Document Type: Article

References (49)

1. Berenguer M,. Recurrent allograft disease: viral hepatitis. Acta Gastroenterol Belg 2005; 68: 337-346. (Pubitemid 41474743)
2. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-836. (Pubitemid 39434314)
3. Berenguer M, Prieto M, Palau A, Rayon JM, Carrasco D, Juan FS, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003; 9: 228-235. (Pubitemid 36322323)
4. Burra P,. Hepatitis C. Semin Liver Dis 2009; 29: 53-65.
5. Gane EJ,. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (Suppl 2): S36-S44.
6. Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067-1076. (Pubitemid 44063780)
7. Neumann U, Puhl G, Bahra M, Berg T, Langrehr JM, Neuhaus R, Neuhaus P,. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82: 43-47. (Pubitemid 44296976)
8. Schuppan D, Krebs A, Bauer M, Hahn EG,. Hepatitis C and liver fibrosis. Cell Death Differ 2003; 10 (Suppl 1): S59-S67. (Pubitemid 36511853)
9. Friedman SL,. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250. (Pubitemid 30081976)
10. Bissell DM,. Chronic liver injury, TGF-beta, and cancer. Exp Mol Med 2001; 33: 179-190. (Pubitemid 34534275)
11. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S,. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7: d793-d807.
12. Everson GT,. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8 (Suppl): S19-S27. (Pubitemid 35154039)
13. Berenguer M, Lopez-Labrador FX, Wright TL,. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666-678. (Pubitemid 33078280)
14. Bahra M, Jacob D, Neumann UP, Spies F, Langrehr JM, Berg T, et al. Influence of donor histology on outcome in patients undergoing transplantation for hepatitis C. Transplantation 2007; 84: 144-148. (Pubitemid 47205746)
15. Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH,. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5: 549-557. (Pubitemid 40313347)
16. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-833. (Pubitemid 30169926)
17. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
18. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
19. Gomez-Mateo J, Marin L, Lopez-Alvarez MR, Moya-Quiles MR, Miras M, Marin-Moreno I, et al. TGF-beta1 gene polymorphism in liver graft recipients. Transpl Immunol 2006; 17: 55-57. (Pubitemid 44828795)
20. Ben-Ari Z, Pappo O, Druzd T, Sulkes J, Klein T, Samra Z, et al. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine 2004; 27: 7-14. (Pubitemid 38780932)
21. Ben-Ari Z,. Role of cytokine gene polymorphism in recurrent HCV infection after liver transplantation. Liver Transpl 2006; 12: 1723-1724. (Pubitemid 44742560)
22. Tambur AR, Ortegel JW, Ben-Ari Z, Shabtai E, Klein T, Michowiz R, et al. Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients. Transplantation 2001; 71: 1475-1480. (Pubitemid 32507124)
23. Bahr MJ, el Menuawy M, Boeker KH, Musholt PB, Manns MP, Lichtinghagen R,. Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver Int 2003; 23: 420-425. (Pubitemid 37540980)
24. Pereira FA, Pinheiro da Silva NN, Rodart IF, Carmo TM, Lemaire DC, Reis MG,. Association of TGF-beta1 codon 25 (G915C) polymorphism with hepatitis C virus infection. J Med Virol 2008; 80: 58-64. (Pubitemid 350220089)
25. Gewaltig J, Mangasser-Stephan K, Gartung C, Biesterfeld S, Gressner AM,. Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta 2002; 316: 83-94. (Pubitemid 34028191)
26. Awad M, Pravica V, Perrey C, El Gamel A, Yonan N, Sinnott PJ, Hutchinson IV,. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol 1999; 60: 343-346. (Pubitemid 29239569)
27. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ,. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520. (Pubitemid 24166476)
28. Hubscher SG,. Histological grading and staging in chronic hepatitis: clinical applications and problems. J Hepatol 1998; 29: 1015-1022. (Pubitemid 28559076)
29. Goldin RD, Goldin JG, Burt AD, Dhillon PA, Hubscher S, Wyatt J, Patel N,. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996; 25: 649-654. (Pubitemid 26373881)
30. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV,. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014-1020. (Pubitemid 28513380)
31. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684. (Pubitemid 30180389)
32. Barrett S, Collins M, Kenny C, Ryan E, Keane CO, Crowe J,. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 2003; 71: 212-218. (Pubitemid 37048464)
33. Mas VR, Fisher RA, Maluf DG, Archer KJ, Contos MJ, Mills SA, et al. Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation. Clin Genet 2004; 65: 191-201. (Pubitemid 38239750)
34. Mangasser-Stephan K, Gressner AM,. Molecular and functional aspects of latent transforming growth factor-beta binding protein: just a masking protein? Cell Tissue Res 1999; 297: 363-370. (Pubitemid 29410526)
35. Hughes JR, Hughes VF, Trull AK, Metcalfe SM,. Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. Transplantation 1999; 68: 583-586. (Pubitemid 29416639)
36. Fredericks S, Holt DW,. TGF-beta quantitation can be tricky. Transplantation 1999; 68: 468-469.
37. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001; 8: 430-437. (Pubitemid 35013568)
38. Castilla A, Prieto J, Fausto N,. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 1991; 324: 933-940.
39. Osterreicher CH, Datz C, Stickel F, Hellerbrand C, Penz M, Hofer H, et al. TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine 2005; 31: 142-148. (Pubitemid 40910230)
40. Wasmuth HE, Lammert F, Matern S,. Genetic risk factors for hepatic fibrosis in chronic liver diseases [in German]. Med Klin (Munich) 2003; 98: 754-762. (Pubitemid 38029674)
41. Stickel F, Osterreicher CH,. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol 2006; 41: 209-224.
42. Osterreicher CH, Halangk J, Berg T, Patsenker E, Homann N, Hellerbrand C, et al. Evaluation of the transforming growth factor beta1 codon 25 (Arg - >Pro) polymorphism in alcoholic liver disease. Cytokine 2008; 42: 18-23.
43. Moroso V, Metselaar HJ, Mancham S, Tilanus HW, Eissens D, van der Meer A, et al. Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transpl 2010; 16: 895-908.
44. Gawrieh S, Papouchado BG, Burgart LJ, Kobayashi S, Charlton MR, Gores GJ,. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 2005; 11: 1207-1213. (Pubitemid 41511934)
45. Cisneros L, Londono MC, Blasco C, Bataller R, Miquel R, Bruguera M, et al. Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C. Liver Transpl 2007; 13: 1017-1027. (Pubitemid 47163195)
46. Bataller R, North KE, Brenner DA,. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37: 493-503. (Pubitemid 36258768)
47. Derynck R, Rhee L, Chen EY, Van Tilburg A,. Intron-exon structure of the human transforming growth factor-beta precursor gene. Nucleic Acids Res 1987; 15: 3188-3189.
48. Tiret L, Amouyel P, Rakotovao R, Cambien F, Ducimetiere P,. Testing for association between disease and linked marker loci: a log-linear-model analysis. Am J Hum Genet 1991; 48: 926-934. (Pubitemid 21891636)
49. Abbas Z, Moatter T, Hussainy A, Jafri W,. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol 2005; 11: 6656-6661. (Pubitemid 43072706)